Skip to content

The latest company news, press releases, and resources about Servier and everything our company has to offer.

Advanced Search
  • servier logo
     
    01.09.2025
    Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors
  • servier logo
     
    11.19.2024
    Servier Partners With Local Cancer Center to Support Research Graduate Students in the Boston Area
  • servier logo
     
    11.13.2024
    Servier to Present Data Across its Hematology Portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting
  • servier logo
     
    11.12.2024
    Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
  • servier logo
     
    08.06.2024
    Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma
Show 5102550100 per page
Media Contacts

Servier Media Relations
USmediarelations@servier.com

Subscribe